Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity.
Metadatos
Mostrar el registro completo del ítemAutor
Cano Muñoz, Mario; Polo Megías, Daniel; Gavira Gallardo, José Antonio; Rodríguez López, María J.; Conejero Lara, FranciscoEditorial
Elsevier
Materia
COVID-19 Fusion inhibitor Vaccine
Fecha
2022-12-01Referencia bibliográfica
Published version: Mario Cano-Muñoz... [et al.]. Novel chimeric proteins mimicking SARS-CoV-2 spike epitopes with broad inhibitory activity, International Journal of Biological Macromolecules, Volume 222, Part B, 2022, Pages 2467-2478, ISSN 0141-8130, [https://doi.org/10.1016/j.ijbiomac.2022.10.031]
Patrocinador
This work was supported by grants CV20.26565 from the Consejería de Economía y Conocimiento, Junta de Andalucía (Spain), PID2019.107515RB.C21 from the Spanish State Research Agency (SRA/10.13039/501100011033), and co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future. The work performed in C.M.’s laboratory was supported by grants from ANRS (Agence Nationale de Recherches sur le SIDA et les h´epatites virales), the Investissements d’Avenir program managed by the ANR under reference ANR-10-LABX-77 and EHVA (No. 681032, Horizon 2020). Work in S.B.’s laboratory was supported by grants from the Agence Nationale de la Recherche (ANR) (ANR-11-LABX-0070_TRANSPLANTEX), the INSERM (UMR_S1109), the Institut Universitaire de France (IUF), all the University of Strasbourg (IDEX UNISTRA), the European Regional Development Fund (European Union) INTERREG V program (project no. 3.2 TRIDIAG) and MSD-Avenir grant AUTOGEN.Resumen
SARS-CoV-2 spike (S) protein mediates virus attachment to the cells and fusion between viral and cell membranes.
Membrane fusion is driven by mutual interaction between the highly conserved heptad-repeat regions 1
and 2 (HR1 and HR2) of the S2 subunit of the spike. For this reason, these S2 regions are interesting therapeutic
targets for COVID-19. Although HR1 and HR2 have been described as transiently exposed during the fusion
process, no significant antibody responses against these S2 regions have been reported. Here we designed
chimeric proteins that imitate highly stable HR1 helical trimers and strongly bind to HR2. The proteins have
broad inhibitory activity against WT B.1 and BA.1 viruses. Sera from COVID-19 convalescent donors showed
significant levels of reactive antibodies (IgG and IgA) against the HR1 mimetic proteins, whereas these antibody
responses were absent in sera from uninfected donors. Moreover, both inhibitory activity and antigenicity of the
proteins correlate positively with their structural stability but not with the number of amino acid changes in their
HR1 sequences, indicating a conformational and conserved nature of the involved epitopes. Our results reveal
previously undetected spike epitopes that may guide the design of new robust COVID-19 vaccines and therapies.